Impact Factor
3.05
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.87
292 total citations
h5-index
26
h5 depth signal
Cited share
69.5%
116 of 167
Total citations
292
Citation footprint
Metric signal
1.58
External metric anchor
Self-citation
3.8%
11 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
549
United States
85
India
65
Germany
32
Italy
26
Citing Fields of Research
Noncoding RNA
269
Oncology
234
Cancer & Development
160
Radiation & Isotope-Based Techniques
129
Liver & Colon Cancer
86
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,498
Articles tracked across the journal lifetime
Indexed publication set
167
116 cited publications
Last 12 months
110
9.2 publications/month
Open access share
0.9%
1 OA publications in the last year
Leading citing country
China
549 citing publications
Leading citing field
Noncoding RNA
269 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v15n1, Feb. 2000-
v15n1, Feb. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Diagnostic & Therapeutic Ultrasound
Noncoding RNA
Immunology
Liver & Colon Cancer
Lung Cancer
Prostate Cancer
Broad Categories
Neoplasms
Pharmacology
Radiotherapy
Therapeutics
Noncoding RNA
Immunotherapy
Radiation & Isotope-Based Techniques
Prostate Cancer
Immunology
Liver & Colon Cancer
MeSH Descriptors
Biological Products
Neoplasms
Radioisotopes
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/10849785261497227
Open DOI
A Hierarchical Framework for Autonomous Macrophage Migration Based on Exploration and Exploitation
Background: Macrophage migration is vital in cancer therapy, as it contributes to the elimination of cancer cells and enables targeted drug delivery. However, the natural migratory ability of macrophage is limited, and the location of ca...
02
DOI 10.1177/10849785261486288
Open DOI
Radioimmunotherapy: Mechanisms, Strategies, and Advances in Therapeutic Enhancement
Radioimmunotherapy (RIT) represents a paradigm shift in precision cancer therapy by integrating the molecular specificity of monoclonal antibodies with the cytotoxic potential of therapeutic radionuclides. However, the therapeutic succes...
03
DOI 10.1177/10849785261476936
Open DOI
Focused Ultrasound–Enhanced Delivery of ED5, a CK1α-Targeting Oleanolic Acid Analogue, Suppresses Glioma Growth via MAPK–ROS–ERS Pathway Modulation
Aim: The objective of this study was to assess the anticancer efficacy of ED5, a new oleanolic acid (OA) analogue and selective casein kinase 1α (CK1α) inhibitor, and to ascertain if focused ultrasound (FUS) can improve its delivery and ...
04
DOI 10.1177/10849785261486278
Open DOI
Theranostic Radiopharmaceutical-Guided Robotic Surgery for Precision Tumor Resection and Targeted Elimination of Residual Disease in Digestive System Malignancies
Background: Digestive system malignancies frequently recur because occult lesions and microscopic residual disease may persist despite apparently complete resection. The authors evaluated an integrated fibroblast activation protein (FAP)...
05
DOI 10.1177/10849785261458478
Open DOI
Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis
Objective: Particularly for patients with bone-dominant illness, targeted radionuclide treatments are becoming a viable treatment option for metastatic prostate cancer (PCa). Precision treatment selection and improved therapeutic outcome...
06
DOI 10.1177/10849785261458444
Open DOI
Prediction of the Efficacy of PA-TACE in Patients with Clearly Defined Hepatocellular Carcinoma by Imaging Combined with Serology: A Retrospective Cohort Study with a Two-Center Follow-Up of up to 12 Years
Objective: The purpose of this study was to determine which patients with hepatocellular carcinoma (HCC) actually benefit from Postoperative adjuvant Transarterial chemoembolization (PA-TACE) and to develop a reliable predictive model fo...
07
DOI 10.1177/10849785261479557
Open DOI
Pharmacokinetic Evaluation of Fibroblast Activation Protein-Targeted Radiopharmaceutical Uptake in Low-Stage Rectal Cancer Tumor Microenvironment
Purpose:: Radionuclide therapy targeting fibroblast activation protein (FAP) offers an effective treatment for tumors with high FAP expression, such as those imaged with 68 Ga-fibroblast activation protein inhibitor (FAPI) and treated wi...
08
DOI 10.1177/10849785261471259
Open DOI
PWidFHNet: Parallel Wider Forward Harmonic Net to Classify Breast Cancer Using Histopathological Images
Background/Purpose:: Breast cancer poses a significant health risk to women worldwide. The timely diagnosis of breast cancer is essential to increase the survival rate and to control premature mortality. However, existing classification ...
09
DOI 10.1177/10849785261460356
Open DOI
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection
Objective: To identify independent prognostic factors in castration-resistant prostate cancer (CRPC) patients with visceral metastases, construct and internally validate a prognostic nomogram for individualized risk stratification, and g...
10
DOI 10.1177/10849785261458520
Open DOI
Development of a 177 Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection
Background:: Hepatocellular carcinoma (HCC) remains the major cause of cancer-related mortality worldwide due to high postoperative recurrence rates and limited treatment options for minimal residual disease (MRD). Methods:: In this stud...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Formed by the union of: Cancer biotherapy, and: Antibody, immunoconjugates, and radiopharmaceuticals, and continues the numbering of the former.